Clinical Trials Logo

Treatment Resistant Depression clinical trials

View clinical trials related to Treatment Resistant Depression.

Filter by:
  • Not yet recruiting  
  • Page 1 ·  Next »

NCT ID: NCT06303739 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Psilocybin-Assisted Therapy in Treatment-Resistant Depression

Start date: March 2024
Phase: Phase 3
Study type: Interventional

The goal of this clinical trial is to test how well psilocybin-assisted therapy works in treating people with depression. The main questions this study aims to answer are: - Does psilocybin with assisted therapy help improve symptoms for people with depression? - How long do the effects of this treatment last? Participants will: - Take part in a couple of screening and preparation visits. - Be given psilocybin in one or two treatment sessions. - Attend a series of follow-up sessions over the following year. - Complete forms and surveys to test how their symptoms have changed and what they thought of their experience. Researchers will also compare whether one treatment or two treatments help improve symptoms more for participants.

NCT ID: NCT06278779 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Comparative Effectiveness Study of Two Forms of Ketamine for Treatment-resistant Depression

TREK
Start date: April 2024
Phase: Phase 4
Study type: Interventional

The goal of this study is to compare the effectiveness of two formulations of ketamine - Spravato® and racemic ketamine - in people with treatment-resistant depression (TRD). The main questions it aims to answer are: - How the two formulations compare in terms of their effectiveness in treating TRD. - How the two formulations compare in their acceptability to patients, safety, effects on patient quality of life and function, and cost effectiveness. Participants will be randomised to receive either Spravato® or racemic ketamine treatment and asked to complete some questionnaires to assess the effects on mood, treatment acceptability, side effects, quality of life and function, and health economic outcomes.

NCT ID: NCT06255561 Not yet recruiting - Clinical trials for Major Depressive Disorder

pBFS Guided rTMS Over Different Targets for Treatment-Resistant Depression

Start date: February 20, 2024
Phase: N/A
Study type: Interventional

To explore the effectiveness and safety of rTMS intervention with different targets in the left prefrontal cortex defined using the pBFS method, in adult patients with moderate and severe depressive disorder. Second, investigate the neural circuit that responds to the rTMS intervention using individualized brain image analysis, which may help to establish an effective target for the neuromodulation of patients with major depressive disorder.

NCT ID: NCT06236711 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Transcranial Direct Current Stimulation (tDCS) as an Adjunctive Treatment for Treatment Resistant Depression (TRD)

Start date: March 2024
Phase: N/A
Study type: Interventional

The researchers are trying to test the feasibility and acceptability of using transcranial Direct Current Stimulation (tDCS) in hospitalized adult patients with Treatment Resistant Depression (TRD), assess for any preliminary effect on depressive and cognitive symptoms, and explore the utility of biomarkers to assess response to tDCS.

NCT ID: NCT06230757 Not yet recruiting - Clinical trials for Major Depressive Disorder

Psilocybin for Treatment-Resistant Depression

Start date: March 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to evaluate the efficacy of psilocybin on the symptom of anhedonia in individuals with treatment-resistant major depressive disorder.

NCT ID: NCT06172413 Not yet recruiting - Clinical trials for Treatment-Resistant Depression

Transcranial Alternating Current Stimulation for Treatment-Resistant Depression

Start date: February 1, 2024
Phase: N/A
Study type: Interventional

This trial aims to investigate the effect of twice-daily 15 mA transcranial alternating current stimulation (tACS) through three conductive electrodes attached to the scalp in subjects with treatment-resistant depression (TRD). Two hundred adult subjects with TRD will be included in this randomized, double-blind, parallelized, multi-centre study. The primary outcome is the change of the Montgomery-Asberg Depression Rating Scale (MADRS) after four weeks of tACS.

NCT ID: NCT06163625 Not yet recruiting - Clinical trials for Major Depressive Disorder

The Impact of Working Memory and Reward Markers on DLPFC Activity in Treatment-resistant Depression

Start date: March 2024
Phase: N/A
Study type: Interventional

Major Depressive Disorder (MDD) is a very common illness that is usually treated with antidepressant medication. Depression can be caused by many things such as childhood experiences, genetics, and changes in the way the body and brain function. For those with depression where medication and psychotherapy have limited benefit, repetitive transcranial magnetic stimulation (rTMS) is an effective treatment. rTMS is a treatment that involves stimulating certain areas of the brain with magnetic field pulses. Over time, the magnetic field pulses can gradually change the activity level of the stimulated brain region. This can be helpful in treating some kinds of psychiatric and neurological disorder, including MDD. It is not fully known how rTMS changes brain activity to improve symptoms of depression. However, certain brain areas responsible for behaviours impacted by depression are underactive in those with depression. One of those brain regions called the dorsolateral prefrontal cortex (DLPFC), and the investigators will target this region using rTMS. By increasing the activity of these regions, rTMS could potentially improve depression symptoms. For participants receiving rTMS, the investigators will be using the participant's brain scan to better understand brain activity of the brain region stimulated by rTMS before and after treatment. In this study, the investigators will be collecting detailed information about participants' psychiatric history and depression symptoms, as well as brain scans and saliva samples. The saliva samples will undergo proteomic (having to do with proteins) analyses to identify biological markers ("biomarkers": biological features (e.g.: gene, protein) that can be measured to indicate factors related to rTMS response. The investigators' goal is to use this information to help us understand whether improvement to rTMS depends on brain activity or proteomic factors localized to two specific behaviours impacted by depression: reward processing and working memory (the capacity to hold information temporarily, such as holding a person's address in mind while listening to instructions about how to get there).

NCT ID: NCT06132178 Not yet recruiting - Depression Clinical Trials

Psilocybin rTMS for Treatment Resistant Depression

PSILOBSD
Start date: January 1, 2024
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and feasibility of sequencing psilocybin therapy with a short-duration, aiTBS protocol (Stanford Accelerated Intelligent Neuromodulation Therapy, or SAINT) in individuals with treatment-resistant major depressive disorder.

NCT ID: NCT06101914 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Studying Patterns in Patient Engagement Among Treatment Resistant Depression Patients

Start date: November 2024
Phase:
Study type: Observational

Clinical studies, with a distinct focus on treatment resistant depression, play a crucial role in evaluating the safety and effectiveness of novel treatments. These trials serve as instrumental means to determine whether new medications surpass conventional therapies, providing substantial evidence for their broader adoption. The primary objective is to meticulously scrutinize trial completion rates and voluntary withdrawals within this specific patient group.

NCT ID: NCT06052137 Not yet recruiting - Clinical trials for Treatment Resistant Depression

Open Label - Personalized Therapeutic Neuromodulation for Anhedonic Depression

Start date: December 2023
Phase: N/A
Study type: Interventional

This study will investigate the anti-anhedonic efficacy of a novel neurostimulation strategy termed accelerated intermittent theta burst stimulation (aiTBS) in participants with treatment resistant depression (TRD).